From Pain to Power: Emotional Transformation Movement Announced by Salvia para el Alma Founder Yuni Krabbe
United States, April 8, 2025 -- The Path of Awakening: Salvia para el Alma's Mission in Motion
In a world grappling with emotional burnout and spiritual disconnection, transformational energy healer and Founder of Salvia para el Alma, Yuni Krabbe, has emerged as a powerful guide leading thousands toward deeper healing and alignment. Through a soul-led fusion of ancestral medicine, Kundalini energy activation, Reiki, and holistic wellness therapies, Krabbe's unique approach offers what many are calling 'soul alchemy'—a complete energetic rebirth that reconnects people to their inner truth.
With a growing presence across sacred retreats, healing ceremonies, and one-on-one transformation journeys, Krabbe's brand isn't just offering services—it's awakening a movement. Rooted in authenticity and spiritual integrity, her work addresses the core emotional wounds that keep people disconnected from their purpose. For Krabbe, the soul is the compass—and healing is the key that unlocks its direction.
Beyond Healing: A Sacred Container for Soul-Led Leadership
Krabbe's mission is distinct: not just to help others feel better, but to activate their truest self. 'What sets me apart is the depth of transformation I offer,' she says. 'I don't do surface-level healing—I go to the root.'
Salvia para el Alma is designed to be a sacred energetic space where individuals feel safe enough to break down, release, and reconstruct themselves from a higher frequency. Her work extends beyond physical or emotional recovery—it is a rite of passage into personal power, divine remembrance, and spiritual sovereignty.
The results are tangible: clients report emotional breakthroughs, energetic recalibrations, and a renewed sense of purpose. 'True healing begins when we stop running from our pain and start listening to its wisdom. That's where freedom lives,' Krabbe says.
Emotional Liberation as the Gateway to Abundance and Purpose
At the heart of Krabbe's work is a simple yet revolutionary truth: emotional liberation is the bridge to all forms of abundance. By unblocking trapped emotions and releasing ancestral patterns, individuals create space for clarity, creativity, and aligned success.
'Our emotional wounds aren't blocks—they're invitations. They hold the wisdom we need to move forward, but only if we're willing to listen,' Krabbe explains. Her holistic methods combine deep energetic release with modern somatic techniques, allowing clients to reset not only their mindset but their entire energetic frequency.
This inner work has catalyzed life changes for clients across the globe—shifts in relationships, careers, and self-worth that ripple outward into families, communities, and beyond.
Global Impact Rooted in Ancient Wisdom
Krabbe's approach blends timeless spiritual principles with today's need for embodied leadership and collective healing. Each experience she facilitates is crafted with intention and reverence for the sacred. Whether guiding Kundalini activations, holding space in a ceremony, or mentoring private clients, she leads with a grounded presence and a powerful energetic signature.
The impact of Salvia para el Alma is already extending beyond borders. Krabbe has facilitated international retreats and continues to draw clients from diverse cultural and spiritual backgrounds seeking deep, authentic transformation. Her vision is global, yet her work remains deeply personal.
'I'm here to ignite the fire within—the leader, the healer, the soul that's been waiting to rise,' she shares. 'This isn't just about wellness. It's about soul revolution.'
A Movement for the Modern Age: Why Salvia para el Alma Stands Out
In a wellness space often filled with trend cycles and surface-level inspiration, Salvia para el Alma's depth offers a refreshing alternative. Krabbe's unique gift lies in how she merges ancient modalities with the present moment's spiritual needs.
Her offerings are not one-size-fits-all. Each experience is intuitively guided, energetically tailored, and rooted in the sacred. Clients often describe sessions with her as life-altering—emerging with a new sense of clarity, sovereignty, and spiritual embodiment.
This energetic integrity, paired with her heart-led leadership, sets Krabbe apart. 'My presence is my power, and my work is a transmission,' she states.
Future Vision: Expanding the Sacred Mission
Looking ahead, Krabbe is focused on expanding the reach of her transformational work across new digital platforms, global collaborations, and soul-centered partnerships. Her goal is to bring emotional healing and energetic awakening into the mainstream conversation, particularly in leadership, wellness, and creative industries.
While remaining true to the spiritual roots of her work, Krabbe is open to aligned opportunities that allow her mission to scale—without compromising the sacred nature of the journey.
'I'm fully committed to expanding this movement worldwide,' she says. 'And I'm calling in those who are ready to co-create from a place of truth, love, and spiritual purpose.'
About Salvia para el Alma
Salvia para el Alma is a transformational healing brand founded by Yuni Krabbe, a trauma specialist and energy healer. Rooted in ancient spiritual practices and modern energy modalities, the brand offers deep emotional release, soul awakening, and holistic alignment through personalized sessions, retreats, and sacred ceremonies. The mission is to help individuals remember who they are, rise into their truth, and activate the power within.
Media Contact
Yuni Krabbe
Founder, Salvia para el Alma
Email:
[email protected]
Website:
salvia-para-el-alma.square.site
Instagram:
@yuni.krabbe
Contact Info:
Name: Yuni Krabbe
Email: Send Email
Organization: Salvia para el Alma
Release ID: 89157081
If you encounter any issues, discrepancies, or concerns regarding the content provided in this press release that require attention or if there is a need for a press release takedown, we kindly request that you notify us without delay at [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our responsive team will be available round-the-clock to address your concerns within 8 hours and take necessary actions to rectify any identified issues or guide you through the removal process. Ensuring accurate and reliable information is fundamental to our mission.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
04-07-2025
- Yahoo
U.S. Complementary and Alternative Medicine Market Competitive Landscape 2025, with Gaia Herbs, Herb Pharm, Pure Encapsulations, NOW Health Group, Nature's Way, Solgar, Twinlab, Ayush Herbs, and more
The U.S. Complementary and Alternative Medicine Market offers significant growth opportunities, driven by increased consumer interest in wellness and non-traditional medicine. Key trends include integration with conventional healthcare, rising chronic and stress-related health issues, and mainstream acceptance of therapies like herbal supplements and mindfulness practices. However, challenges such as regulatory inconsistencies and quality control issues remain. U.S. Complementary and Alternative Medicine Market Dublin, July 04, 2025 (GLOBE NEWSWIRE) -- The "United States Complementary and Alternative Medicine Market, By Region, Competition, Forecast & Opportunities, 2020-2030F" has been added to United States Complementary and Alternative Medicine Market was valued at USD 34.82 Billion in 2024, and is expected to reach USD 125.94 Billion by 2030, rising at a CAGR of 23.87%. The market is expanding rapidly as consumer interest in wellness-oriented lifestyles grows and individuals increasingly explore treatment options beyond traditional medicine. Therapies like acupuncture, homeopathy, naturopathy, energy healing, and aromatherapy are gaining traction across diverse demographics for managing both acute and chronic health concerns. CAM offerings are increasingly integrated with fitness memberships, corporate wellness programs, and digital health subscriptions, contributing to their mainstream acceptance. The popularity of herbal infusions, detox products, and plant-based diets further reflects a cultural pivot toward natural health solutions. According to the NCCIH's 2023 survey, approximately 40% of American adults and 12% of children use complementary therapies. CAM services are being widely incorporated into holistic clinics, hospitals, and telehealth platforms, covering modalities such as yoga, mindfulness, chiropractic care, and herbal supplementation. The younger population is adopting Reiki, sound healing, and crystal therapy, while older adults seek non-invasive methods for pain and sleep disorders. CAM visibility is amplified by wearable health tech, social media influencers, and expanded retail presence in pharmacies and online marketplaces. Key Market Drivers Increase in Chronic and Stress-Related Health Conditions The growing incidence of chronic and stress-induced health conditions is a key driver of the United States Complementary and Alternative Medicine Market. Chronic diseases like cardiovascular disorders, diabetes, arthritis, and respiratory ailments continue to rise, affecting a significant portion of the U.S. population. As of 2023, CDC data shows 6 in 10 U.S. adults live with at least one chronic condition, and 4 in 10 have two or more. Patients are increasingly turning to CAM therapies for their holistic and less invasive approach to long-term disease management. Stress-related issues are also prevalent due to modern lifestyle demands. The American Psychological Association reported that 77% of Americans frequently experience physical symptoms from stress, and 73% report psychological effects. CAM practices such as meditation, acupuncture, herbal therapy, and mindfulness are gaining popularity as non-drug alternatives for mental and emotional well-being. Clinicians are recognizing the value of integrative care models that blend conventional and complementary therapies to address both physical and emotional dimensions of health. The rising emphasis on self-care, wellness, and preventive strategies is further fueling CAM's appeal. Key Market Challenges Lack of Standardized Regulations and Quality Control One of the most significant challenges facing the U.S. CAM market is the lack of consistent regulatory frameworks and standardized quality controls. Unlike conventional pharmaceuticals, many CAM products - including herbal supplements and traditional remedies - do not undergo uniform evaluation for safety and efficacy. This regulatory inconsistency creates uncertainty for both consumers and manufacturers, limiting broader adoption and integration into mainstream healthcare. Quality assurance is another critical issue. Variability in ingredient sourcing, formulation, and production processes leads to inconsistent product quality and therapeutic outcomes. Botanical components, for example, can vary significantly in potency depending on region, harvesting practices, and processing methods. These inconsistencies raise concerns about contamination and mislabeling. The absence of robust quality standards can reduce consumer trust and expose producers to legal risks. The lack of regulatory clarity also discourages investment and innovation, delaying the development of validated, evidence-based CAM solutions. Key Market Trends Integration of CAM into Conventional Healthcare Systems A prominent trend in the U.S. CAM market is its growing integration into mainstream healthcare settings. The Department of Veterans Affairs has significantly expanded its use of Complementary and Integrative Health (CIH) practices to support pain management, mental health, and overall well-being. This move represents a broader push toward patient-centered care that includes both medical and holistic treatment options. Government-backed initiatives further reflect this integration. For instance, in 2023, the Department of Health and Human Services launched a national strategy emphasizing Food Is Medicine (FIM) programs, aligning with CAM's foundational principles. These developments signal increasing institutional support for CAM therapies as part of broader healthcare delivery models. Hospitals, insurers, and public health organizations are recognizing the value of non-invasive, cost-effective interventions in managing chronic diseases and improving patient satisfaction. This institutional adoption is expected to accelerate as more clinical data validates CAM's efficacy and safety. Key Market Players Gaia Herbs, Inc. Herb Pharm, LLC Pure Encapsulations, LLC NOW Health Group, Inc. Nature's Way Products, LLC Solgar, Inc. Traditional Medicinals, Inc. Twinlab Consolidated Holdings, Inc. Ayush Herbs, Inc. Integrative Therapeutics Key Attributes: Report Attribute Details No. of Pages 84 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $34.82 Billion Forecasted Market Value (USD) by 2030 $125.94 Billion Compound Annual Growth Rate 23.8% Regions Covered United States Report Scope: In this report, the United States Complementary and Alternative Medicine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below: United States Complementary and Alternative Medicine Market, By Intervention: Traditional Alternative Medicine/Botanicals Mind Healing Body Healing External Energy Aromatherapy United States Complementary and Alternative Medicine Market, By Distribution Method: Direct Sales E-sales Distance Correspondence United States Complementary and Alternative Medicine Market, By Region: North-East Mid-West West South For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment U.S. Complementary and Alternative Medicine Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Newsweek
16-06-2025
- Newsweek
Woman Told To Put Down Horse, but She Refuses: 'Look at Him Now'
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. A black horse is thriving after his owner refused to follow advice to have him put down. Mandy Helwege, 38, who shares updates on TikTok under the handle @todaywithgus, was devastated when her horse Gusadoo, or Gus, fell seriously ill earlier this year. Many people urged her to consider euthanasia, but she held on to hope. "I wish I could put words to how much he means to me and how connected I am to him, but there just aren't words. He is the greatest gift life has given me," Helwege told Newsweek. "I know there are some cases of sleep deprivation that end in euthanasia, and it is the right thing to do, so I did have that in the back of my mind as something I might have to face, and comments from strangers telling me that was the likely outcome were quite devastating to read. A few of them I knew meant well, while others were pretty coldhearted in their delivery, but they all brought me to my knees at the thought." Helwege said Gus is her first horse after more than 15 years away from the sport. The 13-year-old off-the-track thoroughbred began to collapse from sleep deprivation in February, prompting her to document his condition and share his progress over a three-month journey of rehabilitation. Split image of Gusadoo the black horse, the first showing him battling deprivation and the second of him galloping through the fields. Split image of Gusadoo the black horse, the first showing him battling deprivation and the second of him galloping through the fields. todaywithgus/todaywithgus Helwege said that the road to recovery was far from simple. Over the course of several months, she tried numerous approaches to help Gus, ranging from alternative therapies such as an animal communicator, to extensive diagnostics and evaluations with veterinary teams. Helwege spent thousands of dollars on treatments, medications, and supplements, and said she often encountered professionals who downplayed his symptoms. Still, she refused to give up. "But look at him now," she wrote as the text overlay of his recovery. The breakthrough came when Helwege found the right team of professionals who could address Gus's physical, mental, and spiritual needs. She credits Dr. Rachel Heart Bellini of Heart Equine, Betsy Vonda of Balanced With Betsy, Martine Groeneveld of Green Animal Osteopathy, Dr. Heather Finn from Equine Performance Integrative Care, and a Reiki practitioner for playing a pivotal role in his recovery. Today, Gus is thriving. His energy has soared, his body has undergone visible changes, and Helwege said his spirit is "glowing from the inside out." While she isn't certain he is sleeping lying down yet, the signs suggest he is—and, most importantly, the collapsing episodes have stopped. "Gus has built up quite the fan club," Helwege said, describing how people from around the world have followed his recovery. "Companies who donated products without an expectation of anything in return in the hope they might help him be more comfortable. Thousands of people showed up for us and rallied behind him, gave so many suggestions, offered so much encouragement and I could never thank them enough." Helwege added: "It amazes me how they can all see the physical and emotional changes in him as well these past few weeks, and I love the way he brings joy to others." One user, Becca Ban, commented: "Thank god you've never given up on him. y'all are soulmates." Another wrote: "It's kinda scary how willing people are to take a perfectly healthy life out of convenience." User Bart shared: "Non-human animals also have the right to be sick, have disabilities, and to be cared for even without knowing what the outcome will be. I have had a similar story with my cat, we gave her time and she have beautiful years ahead of her." "I have never cried so much for something I didn't have any connection to. I'm so happy you didn't give up," another person added. Do you have funny and adorable videos or pictures of your pet you want to share? We want to see the best ones! Send them in to life@ and they could appear on our site.
Hamilton Spectator
11-06-2025
- Hamilton Spectator
Chiesi Group Enters into Worldwide Licensing Agreement with Key2Brain AB to Advance Blood-Brain Barrier-Crossing Therapies for Lysosomal Storage Disorders
Collaboration will leverage Key2Brain's technology to develop blood-brain barrier-crossing enzyme replacement therapies for lysosomal storage disorders Agreement is built on a partnership initiated in 2022, supporting continued development led by positive in vivo proof-of-concept data demonstrating the potential of Key2Brain's technology PARMA, Italy and STOCKHOLM, June 11, 2025 (GLOBE NEWSWIRE) — Chiesi Group and Key2Brain today announced a worldwide license agreement to advance the development of two blood-brain barrier (BBB)-crossing recombinant enzyme replacement therapies (ERT) for lysosomal storage disorders (LSD), including alpha-mannosidosis (aMann) and Krabbe disease (KD), ultra-rare diseases that affect the central nervous system. The agreement also includes a framework for the parties to include additional enzymes into the collaboration, enabling the expansion of Chiesi's BBB-crossing ERT portfolio and further strengthening its development capabilities. The advancement of these programs will also contribute to Key2Brain's goal of establishing its technology as a leading BBB-crossing platform. At Chiesi Group, these programs are spearheaded by Chiesi Global Rare Diseases, the Group's dedicated business unit focused on research, development, and commercialization of therapies for rare and ultra-rare conditions. 'At Chiesi Global Rare Diseases, we are deeply committed to building a sustainable pipeline in rare diseases by embracing emerging technologies that can enhance the treatment landscape,' said Giacomo Chiesi, Executive Vice President, Chiesi Global Rare Diseases. 'This agreement exemplifies that vision— working to address areas of profound unmet medical need, including neurodegenerative manifestations of ultra-rare diseases like alpha-mannosidosis and Krabbe disease. For too many families, there are still no therapeutic options. Our goal is to bring them hope.' Under the terms of the agreement, Key2Brain will provide Chiesi Group with a worldwide, royalty- bearing license to develop and commercialize two BBB-crossing ERTs. This agreement is built on an existing research collaboration that aimed to develop the production of a BBB-crossing recombinant alpha-mannosidase. Key2Brain will receive an upfront payment and is eligible to receive development and sales-based milestone payments and tiered royalties on potential sales. Chiesi Group will fund all research, development, and subsequent commercialization worldwide. As part of this agreement, there is also a possibility, upon mutual agreement, for the parties to expand the license to Key2Brain's BBB-crossing technology platform for the development of additional BBB-crossing ERTs. 'This exciting collaboration continuation with Key2Brain represents a strategic opportunity to build on the progress we've already made together,' said Mitch Goldman, Senior Vice President R&D, Chiesi Global Rare Diseases. 'By combining our deep therapeutic expertise with Key2Brain's proprietary BBB-crossing platform technology, we aim to enhance the biodistribution, efficacy and tolerability of promising therapies that have historically faced challenges reaching the central nervous system. Together, our goal is to unlock new therapeutic pathways for patients with lysosomal storage disorders, ultimately delivering meaningful and lasting innovation.' Elisabet Sjöström, Ph.D., Founder and CEO, Key2Brain, said, 'Expanding our relationship with Chiesi Global Rare Disease allows us to build on a clinically validated foundation to address the neurological complications of lysosomal storage disorders, including alpha-mannosidosis and Krabbe disease. Through this agreement, we aim to accelerate the research of potential breakthrough therapies that address these neurodegenerative conditions. We believe this partnership serves as a testament to the versatility and competitiveness of our BBB-crossing technology, unique features that are being utilized in Key2Brain's development of our proprietary next-generation brain-targeting therapies.' This collaboration leverages Key2Brain's proprietary BBB-crossing platform technology and Chiesi Global Rare Diseases' capabilities and expertise in this ultra-rare disease landscape, creating a path to advance the ongoing aMann-K2B program as well as initiate new preclinical programs that apply Key2Brain's technology to other LSDs. About Chiesi Group Chiesi is a research-oriented international biopharmaceutical group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company's mission is to improve people's quality of life and act responsibly towards both the community and the environment. By changing its legal status to a Benefit Corporation in Italy, the US, France and Colombia, Chiesi's commitment to creating shared value for society as a whole is legally binding and central to company-wide decision-making. As a certified B Corp since 2019, Chiesi is part of a global community of businesses that meet high standards of social and environmental impact. The company aims to reach Net-Zero greenhouse gases (GHG) emissions by 2035. With 90 years of experience, Chiesi is headquartered in Parma (Italy), with 31 affiliates worldwide, and counts more than 7,500 employees. The Group's research and development centre in Parma works alongside 6 other important R&D hubs in France, the US, Canada, China, the UK, and Sweden. For more information visit: About Chiesi Global Rare Diseases Chiesi Global Rare Diseases is a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases. As a family business, Chiesi Group strives to create a world where it is common to have a therapy for all diseases and acts as a force for good, for society and the planet. The goal of the Global Rare Diseases unit is to ensure equal access so as many people as possible can experience their most fulfilling life. The unit collaborates with the rare disease community around the globe to bring voice to underserved people in the health care system. For more information visit: . Follow @ChiesiGlobalRareDiseases on LinkedIn, Facebook, Instagram, X and YouTube. About Key2Brain Key2Brain is a Swedish biotechnology company dedicated to developing next generation brain targeting therapeutics utilizing its proprietary blood-brain barrier-crossing (BBB-crossing) technology. The technology enables efficient brain uptake and broad distribution of CNS-therapeutics, utilizing small and flexible antibody fragments (VHHs). Key2Brain's VHHs can be integrated into a wide range of therapeutic molecules. The pipeline is being developed internally and in partnerships where Key2Brain's team leverages extensive industry experience in biologics and brain-targeting drugs, accelerating the translation from discovery to the clinic. Key2Brain was founded 2020 and is based in Stockholm. For more information visit: About Key2Brain's technology platform Key2Brain's technology enables efficient brain uptake and broad distribution of therapeutics, utilizing small (<15kDa) engineered single domain VHH antibodies with monovalent specificity for the Transferrin Receptor (TfR). The technology provides opportunities for the development of next generation brain targeting across a diverse range of therapeutic areas. Key2Brain's VHH technology can be efficiently integrated into or combined with therapeutic molecules without impacting either the disease target specificity, or the binding of transferrin to TfR. The modular and flexible platform is being applied to peptides, proteins, enzymes, and oligonucleotides. Key2Brain's VHHs can be expressed in both prokaryotic and eukaryotic systems and purified using commercial large-scale affinity purification systems. The proprietary platform includes species cross-reactive (human/primate/mouse) as well as human/primate specific binders together with a humanized TfR mouse model for translational studies. Chiesi Global Rare Diseases Media Contact Sky Striar LifeSci Communications sstriar@ Key2Brain Media Contact Benjamin Nordin, CBO Key2Brain
